EN DE
Watch Citius Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Citius Pharmaceuticals Inc (CTXR) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Citius Pharmaceuticals Inc stock $0.58, price $0.49, upside +18.3%, quality 41 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CP Citius Pharmaceuticals Inc logo Thin data Nov 10, 2026

Citius Pharmaceuticals Inc

CTXR · US
Fairly valued, weak quality

The stock costs 16% less than our calculation considers fair.

Ranks above peers (4/6)
Fair value $0.5832 · Fairly valued
Quality 41/100
Negative free cash flow
Narrow moat 9/100
Thin data
Estimate
Watch Citius Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$56.75 $0.3708 Fair Value $0.5832 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.3708 – $56.75 · fair‑value band $0.4374 – $0.7290 · the $0.4928 price screens below the $0.5832 fair value. As of Nov 10, 2026.

Follow Citius Pharmaceuticals in your weekly email

Every Wednesday you see whether Citius Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Show moreShow less

The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Stock analysis

Citius Pharmaceuticals Inc (CTXR) currently trades at $0.4928, while our estimate is $0.5832, so the stock looks roughly fairly valued today (gap 15.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.4374 (bear) to $0.7290 (bull), the price of $0.4928 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Citius Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$37.4M in FY2025.

Key figures

Market cap $15.5M Micro · P/S ratio 2.18 · EPS (TTM) $−1.75 · Return on equity −81.1% · Return on assets (EBIT) −29.3% (5-year average) · Operating margin −670% · Revenue (TTM) $7.1M · Free cash flow −$26.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 66% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 18%, CTXR screens cheaper than that median.

Fair Value

Bear $0.4374 Fair Value $0.5832 Bull $0.7290
Price $0.4928 · Upside +18.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 57
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 31
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CTXR, get fair value alerts →

Compare Citius Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside +18.3% · Top 25%
Profitability
Return on assets −28.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.23× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.18× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)58 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs CTXR
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs CTXR
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs CTXR
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs CTXR
argenx SE ARGX $971.55 $908.40 −7% vs CTXR
CSL Limited CSL A$201.68 A$181.40 −10% vs CTXR
Moderna, Inc MRNA $250.83 $158.70 −37% vs CTXR
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs CTXR
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs CTXR
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs CTXR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Citius Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Citius Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/CTXR

Frequently asked questions

Is Citius Pharmaceuticals Inc (CTXR) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.5832 versus a price of $0.4928, about +18% upside (fairly valued).
What is the fair value of CTXR?
Our estimate for Citius Pharmaceuticals Inc is $0.5832 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.4928.
What is the quality score of CTXR?
Citius Pharmaceuticals Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Citius Pharmaceuticals Inc (CTXR)?
Our calculated price target is the estimate of $0.5832 (as of Nov 10, 2026). Cautious scenario $0.4374, optimistic scenario $0.7290. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Citius Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at $0.5832, about +18% upside versus a price of $0.4928 (fairly valued). Cautious scenario $0.4374, optimistic scenario $0.7290. The calculation is refreshed regularly with new filings.
What is the revenue of Citius Pharmaceuticals Inc (CTXR)?
Citius Pharmaceuticals Inc reported trailing-twelve-month revenue of about $7.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Citius Pharmaceuticals Inc (CTXR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Citius Pharmaceuticals Inc it is $0.5832 per share (as of Nov 10, 2026), against a price of $0.4928.
Is Citius Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CTXR trades below its calculated fair value: price $0.4928, fair value $0.5832, a gap of about +18% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTXR?
No. The price is what the market pays today ($0.4928); the fair value is what the company's own numbers justify ($0.5832). For Citius Pharmaceuticals Inc the two are $0.0904 per share apart. That gap is exactly why we show both numbers side by side.
How much is Citius Pharmaceuticals Inc worth?
The market values Citius Pharmaceuticals Inc at about $15.5M (market capitalisation, as of Nov 10, 2026). Per share that is $0.4928; our models calculate a fair value of $0.5832 per share.
What do the bullish and bearish scenarios say about CTXR?
Our models span a range for Citius Pharmaceuticals Inc: cautious scenario $0.4374, base $0.5832, optimistic $0.7290 per share (as of Nov 10, 2026, price $0.4928). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Citius Pharmaceuticals Inc (CTXR)?
Balance-sheet figures for Citius Pharmaceuticals Inc (as of Nov 10, 2026): return on equity −81.1%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is CTXR from its 52-week high?
Citius Pharmaceuticals Inc trades at $0.4928, about 66% below its 52-week high of $1.44 and 33% above the low of $0.3708 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5832 is for.
Which stocks are comparable to Citius Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Citius Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.4928, calculated fair value $0.5832 (+18%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Citius Pharmaceuticals Inc currently trades 16% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Citius Pharmaceuticals Inc (CTXR)?
The closing price on Nov 10, 2026 was $0.4928. Our estimate is $0.5832, about +18% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Citius Pharmaceuticals Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Citius Pharmaceuticals Inc

How large is the market capitalisation of Citius Pharmaceuticals Inc (CTXR)?
The market capitalisation of Citius Pharmaceuticals Inc is $15.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Citius Pharmaceuticals Inc (CTXR)?
The price-to-sales ratio of Citius Pharmaceuticals Inc is 2.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Citius Pharmaceuticals Inc (CTXR)?
Earnings per share at Citius Pharmaceuticals Inc are $−1.75. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Citius Pharmaceuticals Inc (CTXR)?
The return on equity (ROE) of Citius Pharmaceuticals Inc is −81.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Citius Pharmaceuticals Inc (CTXR)?
On an EBIT basis the return on assets of Citius Pharmaceuticals Inc is −29.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Citius Pharmaceuticals Inc (CTXR)?
The operating margin of Citius Pharmaceuticals Inc is −670% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Citius Pharmaceuticals Inc (CTXR) generate?
The free cash flow of Citius Pharmaceuticals Inc is −$26.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Citius Pharmaceuticals Inc (CTXR) hold?
Citius Pharmaceuticals Inc holds more cash than debt, $2.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Citius Pharmaceuticals Inc in the live analysis

One click puts Citius Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.